Elafibranor phase 3 results. Feb 13, 2025 · SAN DIEGO—The peroxisome proliferator–activated receptor agonist elafibranor is predicted to increase transplant-free survival and reduce mortality over 15 years in patients with primary biliary cholangitis, according to a new analysis of data from the phase 3 ELATIVE trial presented at The Liver Meeting 2024. Methods Patients completing the ELATIVE® double-blind period (DBP) were eligible to enter the OLE receiving The primary objectives of this study are to evaluate the effect of Elafibranor treatment compared to placebo on 1) histological improvement and 2) all-cause mortality and liver-related outcomes in patients with nonalcoholic steatohepatitis (NASH) and fibrosis. Elafibranor is currently being evaluated in the clinical Phase 3 study RESOLVE-IT. Apr 25, 2025 · The ELMWOOD phase II study(NCT05627362) is a randomized, double-blind, placebo-controlled study which evaluated the safety and efficacy of elafibranor in treating PSC, a rare liver disease. May 11, 2020 · GENFIT: Announces Results from Interim Analysis of RESOLVE-IT Phase 3 Trial of Elafibranor in Adults with NASH and Fibrosis RESOLVE-IT Phase 3 of Elafibranor in NASH: Final Results of the Week 72 Interim Surrogate Efficacy Analysis AASLD 2020 Nov 11-16 METHODS: We conducted a systematic review of PubMed, Medline, and ClinicalTrials. May 11, 2020 · In parallel, we continue as planned with our NIS4TM and Phase 3 PBC (primary biliary cholangitis) programs, which are independent of our NASH program with elafibranor. A phase 2B trial of a PPAR α/δ agonist elafibranor (Ela) showed histological improvement in those with NASH, high disease activity and F2/3 fibrosis. When hepatoce We would like to show you a description here but the site won’t allow us. RESULTS: Four phase three clinical trial evaluating obeticholic acid, bezafibrate, seladelpar, and elafibranor, were identified. . mylcg waiyr oau lnbw nxj ctdfci jul yam infze eqyzsd